Dupixent Lawyers To Meet With Court for Initial Conference in T-Cell Lymphoma Lawsuit

The early proceedings in this Dupixent T-cell lymphoma lawsuit could guide how future claims against the manufacturer of the inflammatory treatment injections move forward.

Attorneys involved in a lawsuit linking Dupixent to a fatal case of T-cell lymphoma will talk with a federal magistrate judge for the first time in early December, to discuss how the court should manage pretrial proceedings in the claim, which could be the first of dozens of Dupixent lawsuits filed in the coming months.

Nearly a year after Tennessee resident Cynthia Marie Hyde died from peripheral T-cell lymphoma, her daughter, Chandra Richardson, filed a Dupixent wrongful death lawsuit on October 1, alleging that Regeneron Pharmaceuticals and Sanofi-Aventis U.S. Inc. knew or should have known that their inflammatory treatment could accelerate the risk of cancer, yet failed to adequately warn users or the medical community.

Dupixent (dupilumab) is an injectable medication given every two to four weeks to treat chronic inflammatory conditions such as asthma, eczema and chronic sinusitis with nasal polyps. Approved by the FDA in 2017, the drug works by targeting specific immune pathways involved in inflammation.

However, over the past year, research has emerged that links Dupixent side effects to increased T-cell lymphoma risks, including cutaneous T-cell lymphoma (CTCL) and PTCL, the latter of which led to Hyde’s death.

After the lawsuit was filed it was assigned to U.S. District Judge Eli J. Richardson, who issued a Notice of Setting of Initial Case Management Conference (PDF), scheduling the first telephone conference between the parties for December 8, 2025. The notice indicates lead trial counsel for each party is required to attend.

The initial case management conference will be overseen by Magistrate Judge Alistair Newbern, who will discuss with the parties the scheduling of key dates and deadlines in the litigation, as well as the potential trial. The notice also calls on the parties to propose an initial case management order no later than three business days before the December 8 conference.

On October 2, Judge Richardson issued a follow-up court order (PDF), indicating that the parties should also be prepared to discuss the substantive factual and legal issues likely to impact the litigation and what currently stands in the way of a potential Dupixent settlement agreement. In addition, the parties should tell Magistrate Judge Newbern whether either party is ready or expects to file any dispositive motions.

Dupixent T-Cell Lymphoma Lawsuits

The wrongful death claim filed by Hyde’s daughter is one of the first of what is expected to be a series of Dupixent t-cell lymphoma lawsuits likely to be brought against the drug makers.

The early management of this case could play an important role in how the litigation moves forward in other claims, which are likely to raise similar allegations.

Law firms are now investigating complaints like Richardson’s for individuals who were prescribed the drug for any of its approved uses and later diagnosed with PTCL or another T-cell lymphoma subtype.

To receive a free consultation to determine if you or a loved one may be eligible to file a lawsuit, submit information for review by a Dupixent lawyer.